TABLE 3.
PRIMARY AND SECONDARY OUTCOMES IN THE ENTIRE STUDY POPULATION AT THE END OF THE SALMETEROL TREATMENT PERIOD (VISIT 3) AND AS CHANGE FROM VISIT 2
| Outcomes | End of Treatment (n = 26) | Change (V2 to V3) (n = 26) | P Value* |
|---|---|---|---|
| FEV1 preexercise, % predicted | 87.0 ± 2.3 | 4.5 ± 1.8 | 0.09 |
| Morning PEF, L/min | 445.0 ± 19.1 | 38.6 ± 7.6 | 0.00003 |
| ACQ | 0.8 ± 0.1 | −0.4 ± 0.1 | 0.057 |
| FeNO, ppb | 45.3 ± 5.6 | −6.1 ± 4.3 | 0.36 |
| FEV1 9 h after salmeterol, % predicted | 90.2 ± 2.1 | −1.5 ± 0.9 | 0.71 |
| FEV1 9 h after salmeterol, % increase from preexercise | 3.5 ± 1.2 | −6.0 ± 1.6 | 0.002 |
| Max FEV1 % fall after exercise | 22.8 ± 3.2 | 14.7 ± 2.7 | 0.00001 |
| % Bronchoprotection | 18.9 ± 11.5 | −51.4 ± 10.2 | 0.0001 |
Definition of abbreviations: ACQ = asthma control questionnaire; FeNO = exhaled nitric oxide.
Data are expressed as mean ± SE.
*
Comparison between the beginning and the end of treatment.